Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/6882
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorCastilho-Martins, A.es
dc.contributor.authorTavares, Marina F. M.es
dc.contributor.authorBarbas Arribas, Coral.es
dc.contributor.authorLópez Gonzálvez, María Ángeleses
dc.contributor.authorRivas, Luises
dc.contributor.otherUniversidad San Pablo-CEU. Facultad de Farmacia. Centro de Excelencia Metabolómica y Bioanálisis-
dc.creatorRojo Blanco, Davides
dc.creatorCanuto, Gisele A. B.es
dc.date2015-
dc.date.accessioned2015-02-05T11:50:51Z-
dc.date.available2015-02-05T11:50:51Z-
dc.date.issued2015-02-05-
dc.identifier.urihttp://hdl.handle.net/10637/6882-
dc.descriptionSample type: Promastigote cell cultures. Once they reached a mid- exponential phase of growth (8.000.000 promastigotes/mL) they were transferred into the same volume of fresh RPMI medium, and incubated or not with 120 µmol/L potassium antimony(III) tartrate for 12h. The preparation for 13C analysis was done by growing the parasites in RPMI where L-arginine was substituted by 13C L-arginine for 14h. -------------------------------------------------------------------- Investigated group : - ST: susceptible strain treated. - SNT: susceptible strain non–treated (controls). - R: resistant strain to Sb3+. - QC: Quality Controls samples were prepared by pooling equal volumes of each sample from all groups. --------------------------------------------------------------- Techniques: - CE-ESI-MS: CE (7100 Agilent Technologies), TOF (6224 Agilent Technologies). - LC-ESI-MS: LC (1200 series, Agilent Technologies), QTOF (6520 Agilent Technologies). - GC-EI-MS: GC (Agilent Technologies 7890A), Q (Agilent Technologies 5975)en
dc.description.abstractAbstract: The goal of this work is to test whether a metabolomic platform, gathering different complementary analytical techniques, will improve the metabolite coverage achieved by single separation techniques, applied to the mechanism of action and resistance to Sb3+ in Leishmania infantum. This was accomplished first through the untargeted analysis of metabolic snapshots of treated and untreated parasites both resistant and responders, utilizing a multiplatform approach to give the widest as possible coverage of the metabolome, and additionally through novel monitoring of the origin of the detected alterations through a 13C traceability experiment. ------------------------------------------------------------- Resumen: El objetivo de este trabajo es comprobar los mecanismos de acción y resistencia a Sb3+ en Leishmania infantum desde un enfoque multiplataforma con técnicas analíticas complementarias y conseguir una mejora en la cobertura metabólica global. Primeramente se analizaron los perfiles metabólicos en parásitos tratados, no tratados y resistentes. Obtenidas las pertinentes conclusiones, se procedió a la monitorización del origen de las alteraciones metabólicas detectadas a través de una novedosa metodología para la trazabilidad de 13C.en
dc.formatapplication/xmles
dc.language.isospes
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.eses
dc.subjectLeishmania infantumes
dc.subjectMetabolomicses
dc.subjectAntimonial action and resistancees
dc.subject13C-Argininees
dc.subjectMultiplatform approaches
dc.titleA multiplatform metabolomic approach to the basis of antimonial action and resistance in Leishmania infantumen
dc.title.alternativeAnálisis de Leishmania tratada con antimonioes
dc.typeDatos de investigaciónes
europeana.dataProviderUNIVERSIDAD SAN PABLO CEU-
europeana.isShownAthttp://hdl.handle.net/10637/6882-
europeana.objecthttp://repositorioinstitucional.ceu.es/visor/libros/613952/thumb_europeana/613952.jpg-
europeana.providerHispana-
europeana.rightshttp://creativecommons.org/publicdomain/zero/1.0/-
europeana.typeTEXT-
dc.centroUniversidad San Pablo-CEU-
Aparece en las colecciones: Facultad de Farmacia




Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.